Incyte Corporation
Incyte Corporation (0J9P.L) Financial Performance & Income Statement Overview
Explore the financials of Incyte Corporation (0J9P.L), including yearly and quarterly data on income, cash flow, and balance sheets.
Incyte Corporation (0J9P.L) Income Statement & Financial Overview
Explore comprehensive income reports for Incyte Corporation 0J9P.L, broken down by year and quarter.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $1.05B | $1.18B | $1.14B | $1.04B |
| Cost of Revenue | $73.20M | $88.50M | $86.00M | $92.98M |
| Gross Profit | $979.70M | $1.09B | $1.05B | $950.78M |
| Gross Profit Ratio | $0.93 | $0.92 | $0.92 | $0.91 |
| R&D Expenses | $437.28M | $466.03M | $573.17M | $1.14B |
| SG&A Expenses | $325.69M | $326.80M | $309.20M | $289.63M |
| Operating Expenses | $774.53M | $788.68M | $905.79M | $1.43B |
| Total Costs & Expenses | $847.73M | $877.18M | $991.79M | $1.52B |
| Interest Income | $22.93M | $10.002M | $24.20M | $49.77M |
| Interest Expense | $660000.00 | $419000.00 | $774000.00 | $657000.00 |
| Depreciation & Amortization | $22.36M | $22.73M | $22.52M | $22.05M |
| EBITDA | $257.21M | $336.88M | $179.82M | -$367.07M |
| EBITDA Ratio | $0.24 | $0.29 | $0.16 | -$0.35 |
| Operating Income | $205.17M | $301.51M | $146.09M | -$477.24M |
| Operating Income Ratio | $0.19 | $0.26 | $0.13 | -$0.46 |
| Other Income/Expenses (Net) | $29.02M | $12.21M | $10.44M | $88.35M |
| Income Before Tax | $234.19M | $313.72M | $156.52M | -$389.78M |
| Income Before Tax Ratio | $0.22 | $0.27 | $0.14 | -$0.37 |
| Income Tax Expense | $75.99M | $112.51M | $50.07M | $54.82M |
| Net Income | $158.20M | $201.21M | $106.46M | -$444.60M |
| Net Income Ratio | $0.15 | $0.17 | $0.09 | -$0.43 |
| EPS | $0.82 | $0.97 | $0.55 | -$2.04 |
| Diluted EPS | $0.80 | $0.96 | $0.54 | -$2.04 |
| Weighted Avg Shares Outstanding | $193.71M | $207.11M | $192.63M | $218.18M |
| Weighted Avg Shares Outstanding (Diluted) | $198.20M | $210.53M | $195.84M | $218.18M |
Over the last four quarters, Incyte Corporation achieved steady financial progress, growing revenue from $1.04B in Q2 2024 to $1.05B in Q1 2025. Gross profit stayed firm with margins at 93% in Q1 2025 versus 91% in Q2 2024. Operating income totaled $205.17M in Q1 2025, maintaining a 19% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at $257.21M. Net income dropped to $158.20M, with EPS at $0.82. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan